What is the most promising strategy to defeat coronaviruses?

2020 May 13 News /BioValleyBIOON / - In an unprecedented effort, tens of thousands of researchers and clinicians around the world We are a race against time to develop a method for the treatment of COVID-19, and better vaccinediagnostic testsCOVID-19 is a disease caused by SARS-CoV-2 viruson COVID-19 has more than 1,650 articles were listed in the Google Scholar database, etc., will also increase the dozens every dayClinicalTrials.gov registration website lists more than 460ongoing clinical trials19 COVID-, although most are still in the early stagesGivenexperimental methodsdiversity of these studies, clinical strategies for possible systematic review is timely and usefulSource: NIAIDin a new study published in the FrontiersinMicrobiology for researchers and non-professionals, the experts reviewed from the University of North Carolina at Chapel Hill for possible danger coronavirus treatment strategyIncluding causing COVID-19 of SARS-CoV-2, caused by the SARS SARS-CoV, the cause MERS MERS-CoV and other unknown novel coronavirus may arise in the futurethey made the most rapid progress has hope method is to select the antiviral drugs, such as Reid and Western Wei gene therapy University of North Carolina at Chapel Hill epidemiology, Dr RalphBaric microbiology and immunology Distinguished Professor said: "coronavirus on human health and the global economy poses a real threat that we must first consider new strategies to control the SARS-Cov-2 pandemic virus and a number of high threat zoonotic viruses that may arise in the future "
" to help focus global forces seeking treatment, our goal here is to provide a comprehensive resource for SARS so far, including pre-clinical and clinical trials and the results of all of Middle East respiratory syndrome vaccine to possible treatment strategies for SARS-Cov-2 and associated coronavirus "
authors one by one to discuss possible strategies against the coronavirus First, the most effective vaccines In the present case, the most likely successful carrying the receptor binding domain (viral S protein), and allowed to bind to the host cell fusion In addition to traditional attenuated live vaccines, inactivated vaccines and subunit vaccines should be considered modern type of vaccines, such as vaccines based nano particles and DNA / RNA or viral vector vaccine delivery Since S- amino acid sequence of the protein in very different coronavirus (e.g., SARS-Cov there between, and SARS-Cov-2 76-78% similarity), is usually not a vaccine strain against another strain will play a role However, due to the development and testing of new vaccines take one to several years, during which other methods are essential second most likely to be effective broad-spectrum antiviral drugs, such as a nucleoside analog which mimics the viral RNA genome in a base, erroneously incorporated into a nascent RNA strand, thus delaying the copying process However, due to coronavirus have a so-called "proof" enzyme, this mismatch may be cut off an RNA, so most nucleoside analogs can not work well However, β-D-N4- hydroxy cytidine and Western Wei Reid seems to be the exception authors believe that this is the most likely effective drugs third plasma convalescent patients having low levels of antibodies to the virus; or, preferably (but slower development), a monoclonal antibody, separation and mass production through biotechnology This "passive immunity" can give short-term immunity a Source: https: //cn.bing.com discussed a number of choices, from the fusion inhibitor is a protease inhibitor to a human, then immunomodulatory agents, such as corticosteroids and the like Finally, in the author's opinion, the vaccine produced before, the most attractive alternative is to gene therapy by adeno-associated virus (AAV) This requires the antibody, immunoadhesin, an anti-viral peptide immunomodulators and fast, targeted delivery to the upper respiratory tract, to provide short-term protection Because of the rapid turnover of cells here, the risk of toxicity is minimal They estimate that these tools can be developed in a month, tuned and tested The study author Dr LongPingVictorTse says that "passive immunization AAV can be used as a quick alternative It is very simple, containing only two components, viral vectors and antibodies more AAV carrier has been shown in humans to be safe and effective "
", a single dose can produce a protective reaction theory within a week, and continued for more than a year now a higher price can be reduced in the treatment of infectious diseases, infectious diseases because a larger market using AAV treat SARS-CoV-2 may be too late, but for future outbreaks, it is certainly not late "(bio Valley Bioon.com) references: Themostpromisingstrategiesfordefeatingcoronavirus LongpingV.Tseetal, TheCurrentandFutureStateofVaccines, AntiviralsandGeneTherapiesAgainstEmergingCoronaviruses , FrontiersinMicrobiology (2020) .DOI: 10.3389 / fmicb.2020.00658